

## **COMBINED HORMONAL CONTRACEPTION**

### **What's New**

The FSRH Clinical Guidance on Combined Hormonal Contraception has been updated in July 2019 (<https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/>)

### **Key changes**

- A year's supply of the combined pill or patch should usually be prescribed at initial consultation with annual follow-up
- There is no need for CHC follow-up or BP check at 3 months unless there are specific issues or concerns
- Clients should be given information about standard and extended CHC regimens
- Clients opting for an extended regimen should have access to clear written or digital information (fpa leaflets now include this information – see links in appendix)
- Clients should be advised that extended use is outside the product licence
- COCs containing 30mcg or less of ethinylestradiol combined with levonorgestrel or norethisterone are recommended first choice pills (this has been routine practice but was not specified in the previous FSRH guideline)
- Information should be given about the typical use failure rate of CHC which is 9% in the first year of CHC use

### **Combined Oral Contraception (COC)**

- Described as any oral hormonal preparation containing an oestrogen in conjunction with a progestogen.
- In current practice, COCs contain 20 – 35 micrograms (mcg) of ethinylestradiol (EE) in combination with a progestogen.
- Progestogens include the older, '2<sup>nd</sup> generation' progestogens norethisterone, levonorgestrel and norgestimate, and the '3<sup>rd</sup> / 4<sup>th</sup> generation' progestogens desogestrel, gestodene, and drospirenone.
- The primary mode of action of this method is to prevent ovulation. These pills are packed in 21 day packs but are also available as every-day packs with placebo tablets to aid concordance with the method.
- There are 2 products containing oestradiol (Zoely® with oestradiol hemihydrate combined with nomegestrol in a 28 day pack, and Qlaira® with oestradiol valerate combined with dienogest in a 28 day pack), but neither are approved by SMC for contraceptive use within Scotland.

### **Combined Transdermal Patch (CTP)**

- Currently in the UK there is one transdermal contraceptive patch which releases 33.9 micrograms ethinylestradiol and 203 micrograms norelgestromin per 24 hours (Evra®).
- One patch to be applied once weekly for three weeks, followed by a 7 day patch free interval.
- Extended regimens can also be discussed

### **Combined Vaginal Ring (CVR)**

- The combined vaginal ring (Nuvaring®) consists of ethylene vinylacetate (latex-free) and releases 15 micrograms ethinylestradiol and 120 micrograms etonogestrel daily. One ring should be inserted vaginally for 3 weeks of use per cycle.
- This should then be removed and a new ring inserted after a 7-day ring-free break.
- Rings must be kept refrigerated prior to dispensing to the client. Thereafter, they can be stored at room temperature and used within 4 months. Women should therefore only be supplied with up to 3 rings at a time.
- Extended regimens can also be discussed

### **Indications for CHC Use**

- Women wishing to control their fertility or menstrual cycle and who have no contraindications to its use (see UK Medical Eligibility Criteria <http://ukmec.pagelizard.com/2016#sectiona/cover>).
- Women wishing to use CHC for menstrual control should be informed that this is outside the product licence (with the exception of Qlaira).

### **Efficacy**

- A Cochrane review comparing the combined patch, ring and pill has concluded that these methods have similar efficacy:
  - Perfect use: (following directions for use) the failure rate is 0.3%
  - Typical use: (actual use including inconsistent or incorrect use) is 9%.
- **Women should be informed of the typical use failure rate**

The Faculty have recommended caution in women whose weight is greater than 90kg using the CTP, due to concerns over efficacy. This is independent of BMI. These women should consider alternative methods of contraception other than the CTP.

### **Side Effects**

#### **Common side effects**

- Nausea
- Headache
- Mastalgia
- Skin reactions including photosensitivity
- Chloasma
- Reduced menstrual loss
- Unscheduled bleeding
- Amenorrhoea
- Contact lenses may irritate

Women can be reassured there is no evidence suggesting an association between CHC and weight gain.

**Less common side effects**

- Changes in libido
- Mood changes (no evidence causes depression)
- Chorea
- Hypertension
- Impairment of LFTs
- Hepatic tumours

*Further information is available in the Faculty guidance comparing the side effects of the combined hormonal methods.*

**Risks**

At first prescription of CHC all women should be informed that:

- CHC use is safe for the majority but can be associated with rare but serious harms;
- Venous thrombo-embolism (VTE):
  - There is a small increase in the risk of VTE with CHC use.
  - This risk is highest in the first 4 months of CHC use.
  - It reduces but remains stable thereafter.
  - The risk returns to that of non-users within weeks of discontinuation. (see table below).
  - When counselling women it is important to emphasise that while some progestogens within CHCs may be associated with a higher risk of VTE than others, the risk of a venous thrombosis in women who use the CHC is very small – smaller than that associated with pregnancy and the puerperium.

***CHC use and Risk of VTE***

	Risk of VTE per 10,000 women years
Non contraceptive users and not pregnant	2
CHC containing ethinylestradiol plus levonorgestel, norgestimate or norethisterone	5-7
CHC containing etonogestrel (ring) or norelgestromin (patch)	6-12
CHC containing ethinylestradiol plus gestodene, desogestrel, drospirenone or cyproterone	9-12
Pregnancy	29
Immediate Postpartum period	300-400

- There may be a small increase in the risk of heart attack with CHC use. (Please see UKMEC tables)
- There may be an increased stroke risk, particularly in migraine sufferers with associated aura (see UKMEC)
- There is likely to be a small increase in breast cancer risk (RR 1.19 to 1.24) which returns to no increased risk 10 years after stopping CHC. Users of CHCs have not been found to be associated with increased mortality from breast cancer.

- There may be a very small increase in the risk of cervical cancer that increases with increasing duration of use. This returns to that of never-users 10 years after stopping CHC. There is no evidence of any increased cervical cancer risk when CHC is used for less than 5 years
- Use of CHC is associated with a reduced risk of ovarian and endometrial cancer that continues for several decades after stopping.

### **Reasons to Stop Immediately and Seek Medical Advice**

- Unusual severe prolonged headache especially if first time or getting progressively worse
- Sudden partial or complete loss of vision
- Sudden disturbance of hearing or other perceptual disorders
- Dysphasia
- First epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body
- Sudden severe chest pain
- Sudden breathlessness
- Haemoptysis
- Severe pain in calf of one leg
- Blood pressure above systolic 160 mm Hg and diastolic 95 mm Hg
- Detection of a risk factor – see medical eligibility criteria below.

### **Possible Drug Interactions**

It is recommended that you check the current status of drug interaction of new preparations with Medscape Drug Interaction Checker. <http://reference.medscape.com/drug-interactionchecker>, BNF ([www.medicinescomplete.com](http://www.medicinescomplete.com)) and, if necessary, any interaction with HIV drugs ([www.hiv-druginteractions.org](http://www.hiv-druginteractions.org))

### **Ulipristal acetate (ellaOne®)**

- FSRH Guidance on Emergency Contraception recommends that following ellaOne, women should wait for 5 days before commencing any hormonal contraception, as if started sooner it may affect the efficacy of ellaOne.

### **Liver enzyme inducing drugs**

- Increase the metabolism of estradiol and progestogens and the efficacy of CHC may be reduced.
- Risks of CHC use and taking liver enzyme inducing drugs outweigh potential benefits (UKMEC Category 3), and an alternative method unaffected by enzyme-inducing drugs is recommended.
- Short term (< 2months) liver enzyme inducing drug use:  
Can continue using CHC but they should be advised to use additional contraceptive precautions (e.g. condoms) whilst taking the enzyme-inducing drug and for 28 days after stopping treatment. To minimise the risk of contraceptive failure the CEU recommends an extended regimen (taking CHC continuously or tricycling with a shortened pill-/patch- or ring-free interval of 4 days).
- Long term liver enzyme inducing drug use:  
If still chooses to use COC as a long-term method, she should use a regime containing at least 50 micrograms of ethinylestradiol.  
A 50 micrograms EE dose may be made up from an appropriate 30 micrograms plus 20 micrograms preparation.  
An extended or tricycling regime with a pill-free interval of 4 days should be followed  
Additional contraception is not required.

If women are on Rifampicin or Rifabutin, an alternative method of contraception should be advised as the regimen above may not be effective.

- **Breakthrough bleeding:**

This may indicate low serum EE concentrations. If other causes (e.g. chlamydia) have been excluded, the dose of EE can be increased up to a maximum of 70 micrograms EE. For women using the combined contraceptive patch or ring, information should be given on the use of alternative contraceptive methods if liver enzyme-inducers are to be used long term. The use of two patches or two rings is not recommended.

**Lamotrigine:**

Please note that lamotrigine is not a liver enzyme inducing drug and that use of CHC in women taking antiepileptic drugs is UKMEC1.

However, the oestrogen in CHC can reduce lamotrigine levels which may result in change in seizure frequency. Therefore women on lamotrigine should not start CHC without informing their neurologist.

Withdrawal of CHC in a client already on lamotrigine can result in lamotrigine toxicity, and patients should be made aware of this.

Further information is available in the summary of product characteristics (SPC) for lamotrigine: <http://www.medicines.org.uk/emc/>.

### **Antibiotics**

- **Non-enzyme inducing antibiotics:**

The CEU no longer advises that additional precautions are required to maintain contraceptive efficacy when using antibiotics with combined hormonal methods. However if the antibiotics (and/or the illness) caused **vomiting or diarrhoea**, then the usual **additional precautions** relating to these conditions should be observed.

- **Rifampicin:**

Women who are given Rifampicin short term (.e.g. for meningococcal meningitis prophylaxis) should be advised to use a barrier method in addition to COC during treatment and for 28 days after stopping Rifampicin.

### **Anti-obesity medication**

- Orlistat (Xenical/Alli) – these may cause diarrhoea and reduce absorption. Additional precautions are advised in these situations.

Further information regarding the effects of combined hormonal contraception on other medications can be found in FSRH Drug interactions guidance -

<https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/>

### **Assessment of Client Suitability**

**History:**

Clinical history taking and examination allow an assessment of medical eligibility for CHC use and possible contraceptive options for the woman. In this context the history should include relevant social, sexual (to assess risk of sexually transmitted infections (STI's)), medical, family and drug history as well as details of reproductive health and previous contraceptive use.

This history should be updated annually.

**Examination:**

- Blood pressure and BMI should be recorded and noted
- Breast examination, pelvic and genital examinations, cervical cytology screening and routine lab tests do not contribute substantially to CHC safety and are not recommended routinely but should be performed if clinically indicated for other reasons

**Choice of Preparation**

**First Line Choice: Rigevidon**

Aim to choose the lowest dosage of oestrogen and progestogen that

- Maintains efficacy
- Has fewest side effects
- Gives good cycle control
- Takes into account differential risk of VTE
- Is cost effective

A monophasic COC containing 20 - 30 micrograms of ethinylestradiol with norethisterone or levonorgestrel is recommended as first line option. Examples are Rigevidon, Ovranette, Microgynon 30, Loestrin 20 or 30. Tailored regimens may improve bleeding patterns and hence improve compliance. Please see appendix for alternative CHC regimens and key messages for women considering tailored regimens.

Transdermal or intravaginal preparations may be advantageous in situations where GI absorption is compromised e.g. Inflammatory bowel disease, or in situations where this method will improve compliance.

**Table: CHC Preparations**

Monophasic preparations Grouped by progestogen type and generation	Oestrogen dose	Brand names	Net price per 3-cycle pack/£
Norethisterone (1 <sup>st</sup> )	35 micrograms EE	Brevinor®	1.99
		Norimin®	2.28
Levonorgestrel (2 <sup>nd</sup> )	30 micrograms EE	Microgynon 30®	2.82
		Leandra®	2.82
		Ovranette®	2.20
		Rigevidon®	1.89
		Levest®	1.80
Desogestrel (3 <sup>rd</sup> )	30 micrograms EE	Marvelon®	7.10
		Gedarel 30/150®	4.19
		Cimizt®	3.80
	20 micrograms EE	Mercilon®	8.44
		Gedarel 20/150®	5.08
		Bimizza®	5.04
Gestodene (3 <sup>rd</sup> )	30 micrograms EE	Femodene®	6.73
		Katya®	5.03
		Millinette 30/75®	4.12
	20 micrograms EE	Femodette®	8.85
		Sunya®	6.62
		Millinette 20/75®	5.41

Cyproterone (equivalent to 3 <sup>rd</sup> )	35 micrograms EE	Co-cyprindiol	7.71
		Dianette®	7.71
		Clairette®	5.42
Norgestimate (equivalent to 2 <sup>nd</sup> )	35 micrograms EE	Cilest®	7.16
		Cilique®	4.65
		Lizinna®	5.37
Drospirenone (4 <sup>th</sup> )	20 micrograms EE	Eloine®	14.70
		Daylette®	10.50
	30 micrograms EE	Yasmin®	14.70
		Lucette®	9.35
		Yacella®	8.30
		Dretine®	8.30
Triphasic pills with varied progestogens	30 – 40 micrograms EE	TriRegol®	2.87
		Triadene	10.40
Phasic with Dienogest (4 <sup>th</sup> )	1 – 3 mg Estradiol valerate	Qlaira®	25.18
Nomegestrel acetate (4 <sup>th</sup> )	1.5mg Estradiol hemihydrate	Zoely®	16.50
Low Dose Patch with norelgestromin	20 micrograms EE	Evra®	19.51
Intravaginal ring with etonogestrel	15 micrograms EE	Nuvaring®	29.70

**Prices as per BNF December 2019**

**Documentation**

- The full visit history should be completed / updated on NaSH.
- Written method information including information about actions after missed pills, ring or patch and a contact number is given to client.
- Record prescription on NaSH
- Nurse supplying where appropriate under patient group direction.

**Follow Up Arrangements**

**Return Visit:**

- Women can be encouraged to attend their GP for follow-up and ongoing supply of combined hormonal contraception.
- 12 months supply (except for NuvaRing) may be issued to clients at the initial visit and thereafter provided no problems have been identified.
- NuvaRing® must be used within 4 months after dispensing. Clients should therefore only be issued with a 3-month supply at any visit. Even with extended use, no more than one box of 3 rings can be issued at one time

**Start Times:**

<b>Circumstances for CHC start</b>	<b>When to start</b>	<b>Additional contraceptive precautions required</b>
Women having menstrual cycles	Start CHC up to and including day 5 (day 1 for Qlaira®)	None
	At any other time if it is reasonably certain that she is not pregnant (see Quick start protocol)	For 7 days 9 days for Qlaira®
Women with secondary amenorrhoea	At any time, if it is reasonably certain that she is not pregnant	For 7 days 9 days for Qlaira®
Postpartum, not breastfeeding	Start CHC on day 21 postpartum if vaginal delivery and no additional risk factors for VTE = UKMEC 2 (UKMEC 3 if other VTE risk factors)	None
	If >21 days postpartum and cycles have returned as for other women having menstrual cycles	None if Day 1-5 For 7 days if started outwith days 1-5
	If >21 days postpartum and cycles have not returned as for other amenorrhoeic women	For 7 days 9 days for Qlaira®
Postpartum, breastfeeding	Please refer to UKMEC for CHC use under different circumstances	
Post Abortion	Up to and including day 5 post medical or surgical abortion <24 weeks gestation (day 1 for Qlaira®)	None

**Switching from other contraceptive methods:**

All Hormonal methods except IUS: *	CHC can be started immediately if hormonal method used consistently and correctly, or if it is reasonably certain she is not pregnant. If previous method injectable or implant can start CHC at any time up to when repeat injection due or implant removed (not expired)	None if previous method reliably suppresses ovulation  If POP (other than Cerelle®) for 7 days (9 days if Qlaira®)
Switching from IUS	CHC can be started immediately Removal of IUS is not recommended if unprotected intercourse has occurred in the last 7 days due to risk of pregnancy	For 7 days (9 days for Qlaira®) Or defer removal of IUS until new method effective
Switching from IUD	CHC can be started at any time of the cycle	None if up to and including day 5 (IUD can be removed at that time)



		If starting CHC after day 5, required for 7 days (9 days for Qlaira®) and defer removal of IUD if unprotected intercourse in the previous 7 days
Switching from barrier method	CHC can be started at any time. At any other time if it is reasonably certain she is not pregnant.	None if up to and including day 5. If starting CHC after day 5, required For 7 days 9 days for Qlaira®

***\*Please note if changing from one CHC to an alternative CHC and have had a 7 day hormone free interval, additional precautions and need for EC maybe required\****

### **Current Prescribing Guidelines**

#### **Yasmin®**

Yasmin® contains 30 micrograms ethinylestradiol plus 3 micrograms drospirenone (an anti-mineralocorticoid gestogen).

Please note: Yasmin® is non formulary in NHS GGC and non formulary systems may apply. It does not have SMC approval.

#### **Indications:**

This should be offered only as third line oral contraceptive where there have been side effects related to fluid retention, mood change, acne or true weight gain related to oral contraception and other methods of contraception have been discussed. Careful documentation of the side effects should be made. **Clients should have tried at least two COCs with different gestogens. Yasmin is not stocked or supplied from Sandyford. Clients may opt to discuss prescription from GP**

#### **Co-cyprindiol**

Dianette®, Clairette®, Acnecin® and Cicalfem® contains 35 micrograms EE plus 2 micrograms cyproterone acetate and are not licensed as a COC.

Recent data confirms that **co-cyprindiol has a VTE risk which is greater than second generation CHCs, but is equivalent to that of third generation CHC.**

#### **Indications:**


In the UK the CSM advises:

- **Co-cyprindiol is not indicated solely as a contraceptive;** it is a treatment option for women with severe acne, which has not responded to oral antibiotics, or for moderately severe hirsutism.
- It should be withdrawn 3 – 4 months after the treated conditions has resolved or if there is no improvement in symptoms.
- If a women wishes to continue with a combined oral contraceptive pill an alternative preparation should be offered with a progestogen with low androgenic side effects e.g.: gestodene or desogestrel,.
- There are however a number of women whose skin control deteriorates significantly on withdrawal of co-cyprindiol and they should be counselled on an individual basis with regard to the risks and benefits of this preparation for them as it may be that it is on balance appropriate for them to continue with co-cyprindiol, and a 12 month supply can be offered if appropriate.

**Evra® / NuvaRing®**

- If availability of hormone is likely to be improved by the transdermal / transmucosal route of absorption as opposed to the use of an oral preparation (inability to take tablets, bowel disease)
- Where a woman chooses and is suitable for combined hormonal contraception, and continuation of the method would be improved by the transdermal / transmucosal system of a once weekly patch change or four weekly ring change (including one week ring free).
- Cost effectiveness should also be considered with the recent reduction in price per cycle

**Advice for Missed Pills**



**Everyday Pill Regimens**

If a woman misses any inactive pills, she should discard the missed inactive pills and then continue taking pills daily, one each day.

If an active pill is missed, follow the guidance as for missed pills above.

**Missed / Detached Patch or Ring**

<b>Situation</b>	<b>Timeframe</b>	<b>Additional contraceptive protection required?</b>
Extension of patch/ring-free interval	≤ 48 hours > 48 hours	No Yes (7 days) consider EC if unprotected intercourse in patch/ring-free interval
<u>Patch/ring detachment/removal</u>	≤ 48 hours > 48 hours	No (providing there has been consistent and correct use for 7 days prior to removal/detachment) Yes (7 days). Consider EC if patch/ring was detached/removed in week 1 and unprotected intercourse occurred in patch/ring-free interval or week 1
Extended use of patch	≤ 9 days > 9 days	No Yes for 7 days
Extended use of ring	≤ 4 weeks > 4 weeks	No (ring-free interval can be taken) Yes. However, if the woman has worn the ring for > 4 but ≤ 5 weeks, efficacy could be maintained by starting a new ring immediately without a ring-free interval

**Appendix**

**Definition of UK MEC Categories**

<b>UKMEC</b>	<b>DEFINITION OF CATEGORY</b>
<b>CATEGORY 1</b>	A condition for which there is no restriction for the use of the contraceptive method.
<b>CATEGORY 2</b>	A condition where the advantages of using the method generally outweigh the theoretical or proven risks.
<b>CATEGORY 3</b>	A condition where the theoretical or proven risks usually outweigh the advantages of using the method.
<b>CATEGORY 4</b>	A condition which represents an unacceptable health risk if the contraceptive method is used.

**Combined Hormonal Contraception Regimens**

<b>Type of regimen</b>	<b>Period of CHC use</b>	<b>HFI</b>
<b>Standard use</b>	21 days (21 active pills or 1 ring, or 3 patches)	7 days
<b>Tailored use</b>		
<b>Shortened hormone-free interval (HFI)</b>	21 days (21 active pills or 1 ring, or 3 patches)	4 days
<b>Extended use (tricycling)</b>	9 weeks (3 x 21 active pills or 3 rings, or 9 patches used consecutively)	4 or 7 days
<b>Flexible extended use</b>	Continuous use (≥21 days) of active pills, patches or rings until breakthrough bleeding occurs for 3–4 days	4 days
<b>Continuous use</b>	Continuous use of active pills, patches or rings	None

**Key messages for women considering use of tailored CHC regimens**

- ▶ The evidence from studies is that combined hormonal contraception (CHC) is as safe and at least as effective for contraception if it is taken as an extended or continuous regimen as it is when it is taken in a traditional 21/7 cycle.
- ▶ A woman who is using CHC does not need to have a monthly withdrawal bleed to be healthy.
- ▶ There is no build-up of menstrual blood inside a woman who uses CHC for an extended time without a break; extended CHC use keeps the lining of the womb thin.
- ▶ Withdrawal bleeds during cyclical use of CHC have been reported by women who are pregnant; women should not consider monthly bleeds on CHC to be reassurance that they are not pregnant.
- ▶ By using extended or continuous CHC the frequency of withdrawal bleeds and associated symptoms (e.g. headache, mood change) is reduced; this could be useful for women who have heavy or painful bleeding or problematic symptoms associated with the hormone-free interval (HFI).
- ▶ The ovaries start to become active during the traditional 7-day HFI. Fewer and/or shorter breaks in CHC use could mean that the risk of pregnancy could *theoretically* be lower with extended or continuous regimens than if a 7-day break is taken every month.
- ▶ There can be irregular bleeding or spotting in the first few months of CHC use, particularly with extended or continuous regimens; this does not usually mean that there is any medical problem and it generally improves with time.
- ▶ The evidence from studies is that using extended or continuous regimens of CHC does not affect the return of a woman's fertility when she stops CHC.

**References:**

- FSRH UK Medical Eligibility Criteria for contraceptive use (UKMEC2016)
- FSRH Drug Interactions with Hormonal Contraception. January 2017
- FSRH Guideline Emergency Contraception. March 2017
- FSRH Guideline Quick Starting Contraception. April 2017
- FSRH Combined hormonal contraception January 2019, updated July 2019  
<https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/> [accessed December 2019]
- fpa Patient Information Leaflets:

<https://sexwise.fpa.org.uk/resource/your-guide-combined-pill-pdf>

<https://sexwise.fpa.org.uk/sites/default/files/resource/2017-08/contraceptive-patch-your-guide.pdf>

<https://sexwise.fpa.org.uk/sites/default/files/resource/2017-08/contraceptive-vaginal-ring-your-guide.pdf>

- FSRH Venous Thromboembolism (VTE) and Hormonal Contraception Statement. November 2014
- FSRH Clinical Effectiveness Unit. Product Review. 20mcg ethinylestradiol/3mg drospirenone - Eloine®, Daylette®. November 2015